ReviewWorld journal of stem cells2014
Progress of mesenchymal stem cell therapy for neural and retinal diseases.
Review in World journal of stem cells, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Stem cell therapy for inherited retinal diseases: a systematic review and meta-analysis.Stem cell research & therapy · 2023Pooled it
- Stem cell-based therapies for inherited retinal diseases - Translational advances and clinical evidence: A review.Biomolecules & biomedicine · 2026Review
- Rekindling Vision: Innovative Strategies for Treating Retinal Degeneration.International journal of molecular sciences · 2025Review
- Molecular and cellular imaging of the eye.Biomedical optics express · 2024Review
- Therapeutic Potential of Oral-Derived Mesenchymal Stem Cells in Retinal Repair.Stem cell reviews and reports · 2023Review
- Continuous non-adherent culture promotes transdifferentiation of human adipose-derived stem cells into retinal lineage.Open life sciences · 2023Article
- Review
- Immune recognition of syngeneic, allogeneic and xenogeneic stromal cell transplants in healthy retinas.Stem cell research & therapy · 2022Article
- Periodontal ligament stem cells as a promising therapeutic target for neural damage.Stem cell research & therapy · 2022Review
- Extracellular Vesicles from Human Adipose-Derived Mesenchymal Stem Cells: A Review of Common Cargos.Stem cell reviews and reports · 2022Review
- Optical and thermal fields induced in the bone marrow by external laser irradiation.Lasers in medical science · 2022Article
- Intravenous infusion of small umbilical cord mesenchymal stem cells could enhance safety and delay retinal degeneration in RCS rats.BMC ophthalmology · 2022Article
- Stem cell transplantation as a progressing treatment for retinitis pigmentosa.Cell and tissue research · 2022Review
- Bone marrow mesenchymal stem cells and their derived exosomes resolve doxorubicin-induced chemobrain: critical role of their miRNA cargo.Stem cell research & therapy · 2021Article
- Review
- Mitigation of Sodium Iodate-Induced Cytotoxicity in Retinal Pigment Epithelial CellsFrontiers in cell and developmental biology · 2021Article
- Neuroprotection and Axonal Regeneration Induced by Bone Marrow Mesenchymal Stromal Cells Depend on the Type of Transplant.Frontiers in cell and developmental biology · 2021Article
- Retinal Lineage Therapeutic Specific Effect of Human Orbital and Abdominal Adipose-Derived Mesenchymal Stem Cells.Stem cells international · 2021Article
- Comparative Study of a Modified Sub-Tenon's Capsule Injection of Triamcinolone Acetonide and the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Retinitis Pigmentosa Combined With Macular Edema.Frontiers in pharmacology · 2021Article
- Combined Transplantation With Human Mesenchymal Stem Cells Improves Retinal Rescue Effect of Human Fetal RPE Cells in Retinal Degeneration Mouse Model.Investigative ophthalmology & visual science · 2020Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
Complex circuitry and limited regenerative power make central nervous system (CNS) disorders the most challenging and difficult for functional repair. With elusive disease mechanisms, traditional surgical and medical interventions merely slow down the progression of the neurodegenerative diseases. However, the number of neurons still diminishes in many patients. Recently, stem cell therapy has been proposed as a viable option. Mesenchymal stem cells (MSCs), a widely-studied human adult stem cell population, have been discovered for more than 20 years. MSCs have been found all over the body and can be conveniently obtained from different accessible tissues: bone marrow, blood, and adipose and dental tissue. MSCs have high proliferative and differentiation abilities, providing an inexhaustible source of neurons and glia for cell replacement therapy. Moreover, MSCs also show neuroprotective effects without any genetic modification or reprogramming. In addition, the extraordinary immunomodulatory properties of MSCs enable autologous and heterologous transplantation. These qualities heighten the clinical applicability of MSCs when dealing with the pathologies of CNS disorders. Here, we summarize the latest progress of MSC experimental research as well as human clinical trials for neural and retinal diseases. This review article will focus on multiple sclerosis, spinal cord injury, autism, glaucoma, retinitis pigmentosa and age-related macular degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.